Meeting
2020 ASCO Virtual Scientific Program
Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study.
Authors
Jobst C. von Einem
Department of Medicine, Division of Hematology, Oncology, and Tumor Immunology (CCM), Charité Universitaetsmedizin Berlin, Berlin, Germany
Jobst C. von Einem , Sebastian Stintzing , Ludwig Fischer von Weikersthal , Thomas Decker , Alexander Kiani , Ursula Vehling-Kaiser , Salah-Eddin Al-Batran , Tobias Heintges , Christian A. Lerchenmuller , Christoph Kahl , Gernot Seipelt , Martina Stauch , Werner Scheithauer , Joerg Hielscher , Michael Scholz , Dominik Paul Modest , Andreas Jung , Thomas Kirchner , Volker Heinemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Clinical Trial Registration Number
NCT00433927
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4070)
DOI
10.1200/JCO.2020.38.15_suppl.4070
Abstract #
4070
Poster Bd #
62
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS mutated tumors in the randomized German AIO study KRK-0306.
First Author: S. Stintzing
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).
First Author: Karam Ashouri
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Predictive factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer.
First Author: AhReum Lim
Poster
2021 Gastrointestinal Cancers Symposium
Cost-effectiveness of cetuximab + FOLFIRI versus bevacizumab + FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
First Author: Ilse Van Oostrum